Advaxis to fund combination trial with AstraZeneca's MEDI4736
This article was originally published in Scrip
Executive Summary
AstraZeneca's MedImmune subsidiary has entered a clinical trial collaboration with US biotechnology company Advaxis aimed at boosting the companies' distinct investigational cancer immunotherapies by administering them together.